Biohaven's Q3 update: FDA accepts Vyglxia filing, SK Biopharmaceuticals deal pending
Vyglxia resubmission for spinocerebellar ataxia carries a 1Q27 FDA goal date, while the SK Biopharmaceuticals license for opakalim awaits closing after HSR clearance.
SEC filing